[{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"ANA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DA-1241","moa":"Glucose-dependent insulinotropic receptor (GPR119)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Gemphire Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Merger","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Gemphire Therapeutics"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Public Offering","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Licensing Agreement","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ MThera Pharma"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"MThera Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Licensing Agreement","leadProduct":"Dioscorea Extract","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NeuroBo Pharmaceuticals \/ MThera Pharma","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ MThera Pharma"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DA-1241","moa":"||Glucose-dependent insulinotropic receptor (GPR119)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DA-1241","moa":"Glucose-dependent insulinotropic receptor (GPR119)","graph1":"Endocrinology","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DA-1241","moa":"Glucose-dependent insulinotropic receptor (GPR119)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DA-1241","moa":"Glucose-dependent insulinotropic receptor (GPR119)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"DA-1241","moa":"Glucose-dependent insulinotropic receptor (GPR119)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NeuroBo Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"NeuroBo Pharmaceuticals \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"NeuroBo Pharmaceuticals \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"DA-1726","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"NB-02","moa":"AChE","graph1":"Neurology","graph2":"Preclinical","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by NeuroBo Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
